In its complaint, Mylan said it and other generic drug companies should be permitted to enter the market as soon as Lipitor's patent expires, according to the report.
Mylan shares are up 0.7%.
Shares of Mylan Inc. (MYL) are higher after Bloomberg reported that the company sued the US Food and Drug Administration in a move to block India's Ranbaxy Laboratories exclusive rights to sell a generic version of Lipitor, Pfizer
